Detailed answers about THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED, including incorporation, status, business activity, and accounts information.
When was THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED founded?
THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED was officially incorporated on 17 October 2024 and is registered under company number 16024034. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED?
THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED's current status is Active - Proposal to Strike off. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED do?
THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED operates in the following sector: 86220 - Specialists medical practice activities. This provides insight into the company's primary business activity and industry focus.
What is THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED's registered address?
The registered office address of THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED is 35 ELM ROAD, LITTLE LEVER, BOLTON, ENGLAND, BL3 1JL. This is the official address filed with Companies House for legal and statutory correspondence.
Is THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED financially stable?
Financial accounts for THE DERMAGEN CLINIC MEDICAL AESTHETICS LIMITED are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.